{
  "_id": "d99e160560d8683ba9c09b507284e9d090440e5ab78001e47cf644be73458e63",
  "feed": "market-watch",
  "title": "BioNTech CEO reportedly says a different COVID vaccine may be needed by next year",
  "text": "<p>“We have no reason to assume that the next generation virus will be easier to handle for the immune system than the existing generation,” said Şahin, who sees the coming year's focus on booster shots for the vaccinated and a continued effort to vaccinate those who haven't been, according to the FT.</p><p>Last week, financial markets cheered news of Merck MRK and Ridgeback Therapeutics' experimental oral antiviral treatment for COVID-19. The drug, molnupiravir, cut the risk of hospitalization or death by 50% in a Phase 3 trial, and seems to work against the gamma, delta and mu variants in around 40% of participants for whom sequencing was available.&#xa0;</p><p>Read:Why a pill you take at home could change the direction of the pandemic</p><p>Medical experts have warned, though, that Merck's potentially groundbreaking new treatment could be used by some as an excuse not to get vaccinated. “It's not a magic pill,”&#xa0; said Dr. William Schaffner, a professor in the infectious-diseases division at Vanderbilt University Medical Center.</p><p>Read:Fauci says legitimate claims to religious exemptions from vaccine mandates are scarce</p>",
  "published": "2021-10-11T08:51:00.000Z",
  "tags": [
    {
      "id": "US58933Y1055",
      "name": "Merck & Co., Inc.",
      "offsets": [
        {
          "start": 770,
          "end": 775
        },
        {
          "start": 345,
          "end": 350
        }
      ],
      "nexusId": "10042334"
    }
  ]
}